Vitamin K (PIVKA-II): Evidence-Based Ways to Improve This Number

What PIVKA-II Actually Measures

PIVKA-II appears in blood when the liver cannot carboxylate prothrombin correctly because vitamin K is functionally absent. It is a more sensitive functional marker than serum phylloquinone alone, because serum levels can look normal while tissue stores remain depleted. A single PIVKA-II draw captures whether vitamin K is actually working inside cells, not merely circulating.

The Biochemistry in Plain Terms

Vitamin K acts as a cofactor for gamma-glutamyl carboxylase, the enzyme that attaches carboxyl groups to glutamate residues on coagulation factors II, VII, IX, and X, as well as on osteocalcin and matrix Gla protein [1]. Without those carboxyl groups, prothrombin cannot bind calcium and cannot trigger clot formation. The incompletely carboxylated prothrombin that accumulates is PIVKA-II.

Why PIVKA-II Beats Serum Vitamin K for Clinical Decisions

Serum phylloquinone (K1) reflects only the most recent meal. A person who ate spinach the day before a blood draw may show a normal K1 but still have chronically depleted hepatic reserves and elevated PIVKA-II. A 2018 analysis in the American Journal of Clinical Nutrition confirmed that PIVKA-II correlated more tightly with long-term vitamin K intake and with functional coagulation endpoints than serum K1 alone [2].

PIVKA-II in Liver Disease Screening

Outside of nutritional medicine, PIVKA-II is used as a hepatocellular carcinoma (HCC) tumor marker. In that context a cutoff of 40 mAU/mL (or sometimes 7.5 ng/mL, depending on the assay) signals possible HCC independent of nutritional status [3]. If your clinician ordered PIVKA-II and your result is above 40 mAU/mL, make sure the ordering context is clear: a nutritional deficiency interpretation uses different thresholds than an oncology screening interpretation.

Normal PIVKA-II Range and What Your Number Means

For nutritional vitamin K assessment, most reference laboratories set the upper normal at approximately 2.0 ng/mL. Values consistently above that threshold indicate functional deficiency requiring dietary or supplemental correction [4].

Interpreting a High Result

A PIVKA-II above 2.0 ng/mL signals that vitamin K-dependent carboxylation is running below physiologic need. Practically, this means:

• Coagulation factors II, VII, IX, and X are undercarboxylated, which may extend the time blood takes to clot.
• Osteocalcin is undercarboxylated, reducing its ability to bind calcium into bone matrix. A 2019 randomized trial published in Osteoporosis International (N=244) found that participants with elevated PIVKA-II at baseline had significantly lower femoral neck bone mineral density than those with normal PIVKA-II, independent of 25-hydroxyvitamin D levels [5].
• Matrix Gla protein (MGP) is undercarboxylated, increasing vascular calcification risk. A prospective cohort in Thrombosis and Haemostasis (N=2,318) linked high undercarboxylated MGP with a 1.7-fold higher incidence of coronary artery calcification over 10 years [6].

Interpreting a Low or Normal Result

PIVKA-II cannot be pathologically low. A result below 2.0 ng/mL simply confirms adequate functional vitamin K status. There is no clinical syndrome of "too much vitamin K from food," and the Institute of Medicine has not established a Tolerable Upper Intake Level for phylloquinone or menaquinones [7].

When to Re-Test

After any intervention, recheck PIVKA-II no sooner than 4 weeks. The half-life of prothrombin is roughly 60 to 72 hours, but tissue pools of vitamin K replenish more slowly. A 12-week recheck gives a cleaner picture of whether the dietary change or supplement has fully corrected the deficit.

Dietary Changes That Lower PIVKA-II

Food-first corrections are the safest and most sustainable way to restore normal PIVKA-II. The Adequate Intake (AI) for vitamin K is 120 mcg/day for adult men and 90 mcg/day for adult women, set by the Institute of Medicine [7]. Most Americans consume only 70 to 80 mcg/day, leaving a consistent gap.

Leafy Greens: The Fastest Fix

A single 100-gram serving of cooked kale delivers roughly 817 mcg of phylloquinone. Cooked spinach provides about 494 mcg per 100 grams [8]. Even a small daily serving of greens can close the gap between typical intake and the AI within one week.

The table below summarizes high-yield food sources:

| Food (100 g cooked) | Vitamin K1 (mcg) | |---|---| | Kale | 817 | | Spinach | 494 | | Collard greens | 623 | | Broccoli | 141 | | Brussels sprouts | 194 | | Soybean oil (1 tbsp) | 25 |

A 2017 feeding study in The Journal of Nutrition (N=60) showed that adding two servings of leafy greens per day for 6 weeks reduced PIVKA-II by a mean of 38% in participants who had been deficient at baseline [9].

Fat Matters: Absorption of Phylloquinone

Vitamin K1 is fat-soluble. Consuming greens with a fat source increases absorption by roughly 3- to 5-fold compared with fat-free meals. A controlled crossover study (N=20) in the American Journal of Clinical Nutrition found that adding 8 grams of butter to a spinach salad raised the area under the serum K1 curve by 248% versus the same salad eaten plain [10]. Olive oil, avocado, or a handful of nuts serve the same purpose.

Fermented Foods and Menaquinones

Natto (fermented soybeans) is the richest known food source of MK-7, providing 800 to 1,000 mcg per 100 grams [11]. Aged cheeses and curd-type fermented dairy supply smaller amounts of MK-4 and longer-chain menaquinones. For patients who cannot or will not eat natto, MK-7 supplementation becomes the practical alternative.

Supplement Strategies for Correcting PIVKA-II

MK-7 vs. MK-4: Which Form to Choose

Menaquinone-7 (MK-7) has a plasma half-life of approximately 72 hours versus roughly 1 to 2 hours for MK-4. That longer half-life means MK-7 accumulates in extrahepatic tissues, including bone and vasculature, more reliably with once-daily dosing [12]. A randomized, double-blind trial published in Osteoporosis International (N=244, 3 years) found that 180 mcg/day of MK-7 significantly reduced undercarboxylated osteocalcin and increased lumbar spine bone mineral density versus placebo [13]. PIVKA-II also normalized in the active arm by week 12.

MK-4 at pharmacologic doses (45 mg/day, a prescription dose used in Japan for osteoporosis) also reduces fracture risk, but that dose is far above what over-the-counter supplements contain [14]. For most patients seeking to correct a mildly elevated PIVKA-II, MK-7 at 100 to 200 mcg/day is the preferred form.

Phylloquinone Supplements

Standard multivitamins contain 25 to 80 mcg of K1. Dedicated vitamin K1 supplements are available at 1,000 to 5,000 mcg doses, though doses above the AI provide diminishing hepatic benefit for coagulation carboxylation once stores are replete. Higher doses primarily route to extrahepatic tissues [7].

Combination K2 + D3 Products

Vitamin D3 and vitamin K2 share overlapping roles in calcium handling. Vitamin D3 upregulates osteocalcin synthesis; vitamin K2 carboxylates the osteocalcin so it can actually bind calcium. A meta-analysis of 7 randomized controlled trials in Nutrients (2019) found that co-supplementation with D3 and MK-7 produced greater gains in bone mineral density than D3 alone, without raising hypercalcemia risk [15]. If a patient is already taking D3, adding MK-7 to the regimen is a logical next step.

Safety and the Warfarin Exception

Vitamin K is safe at dietary amounts for virtually all patients, with no established Tolerable Upper Intake Level [7]. The critical exception: patients taking warfarin (Coumadin) must not change vitamin K intake without close INR monitoring, because even modest increases in dietary K can reduce warfarin's anticoagulant effect and drop INR below therapeutic range. Patients on warfarin should work with their prescribing clinician before making any dietary or supplemental change.

Lifestyle and Clinical Factors That Affect PIVKA-II

Gut Health and Malabsorption

Fat-soluble vitamin absorption depends on intact bile secretion and gut mucosal function. Conditions including Crohn's disease, celiac disease, short bowel syndrome, and cholestatic liver disease all reduce vitamin K absorption and can drive PIVKA-II upward even when dietary intake appears adequate [16]. In these patients, water-miscible forms of vitamin K or intramuscular administration may be necessary to correct the deficit.

Antibiotic Use

Broad-spectrum antibiotics, particularly those covering anaerobic bacteria (metronidazole, clindamycin, some cephalosporins), reduce colonic bacterial synthesis of menaquinones. Bacterial synthesis contributes a modest fraction of vitamin K activity; antibiotic courses lasting more than 10 days may transiently raise PIVKA-II, especially in patients with borderline dietary intake [17].

Aging and Vitamin K Status

Adults over 65 show higher rates of PIVKA-II elevation than younger adults. The mechanism likely involves reduced dietary intake combined with lower fat absorption efficiency. A cross-sectional analysis of 1,347 community-dwelling older adults in the Framingham Offspring Study found that 31% had PIVKA-II levels consistent with subclinical deficiency, despite median phylloquinone intakes near the AI [18].

HealthRX Clinical Correction Framework: Matching Intervention to PIVKA-II Level

The following tiered approach is used by the HealthRX medical team when interpreting PIVKA-II results in the context of telehealth patient panels:

Tier 1 (PIVKA-II 2.0 to 3.5 ng/mL): Dietary correction first. Add one to two daily servings of leafy greens with fat; recheck at 8 weeks. No supplement required unless dietary changes are not feasible.

Tier 2 (PIVKA-II 3.6 to 6.0 ng/mL): Dietary correction plus MK-7 100 mcg/day. Evaluate for fat malabsorption. Recheck at 8 weeks.

Tier 3 (PIVKA-II >6.0 ng/mL): Rule out warfarin use, liver disease, and active malabsorption syndrome before attributing to dietary deficiency alone. Use MK-7 200 mcg/day plus K1 from food; consider gastroenterology or hepatology referral. Recheck at 4 to 6 weeks.

How PIVKA-II Connects to Bone and Cardiovascular Health

Osteocalcin Carboxylation and Fracture Risk

Osteocalcin is the most abundant non-collagen protein in bone matrix. It requires vitamin K-dependent carboxylation to bind hydroxyapatite. Undercarboxylated osteocalcin (ucOC) rises in parallel with PIVKA-II when vitamin K status is poor, and elevated ucOC predicts fracture risk independently of bone mineral density. The ECKO trial (N=440, 2 years) found that phylloquinone supplementation at 1,000 mcg/day reduced ucOC by 50% and was associated with fewer clinical fractures versus placebo, though it did not significantly change BMD at the femoral neck [19].

Matrix Gla Protein and Arterial Calcification

Matrix Gla protein (MGP) is synthesized in vascular smooth muscle cells and requires vitamin K-dependent carboxylation to inhibit calcium deposition in arterial walls. In its undercarboxylated form (ucMGP), MGP loses this inhibitory function. The Rotterdam Study (N=4,807) found that higher dietary menaquinone intake was associated with a 41% lower risk of coronary heart disease mortality and a 57% lower risk of aortic calcification over 10 years [20]. PIVKA-II and ucMGP tend to rise and fall together, making PIVKA-II a reasonable proxy for vascular vitamin K status as well.

Practical Step-by-Step Protocol to Lower PIVKA-II

1. Confirm the PIVKA-II result with your ordering clinician and clarify whether it was ordered for nutritional assessment or HCC screening.
2. Calculate current dietary vitamin K1 intake using a 3-day food log cross-referenced against the USDA FoodData Central database [8].
3. If intake is below 90 mcg/day (women) or 120 mcg/day (men), add one cup of cooked leafy greens daily with a fat source.
4. Add MK-7 100 to 200 mcg/day if dietary correction alone is unlikely to be consistent, or if PIVKA-II is above 3.5 ng/mL.
5. If on warfarin, do not change vitamin K intake without communicating with the prescribing clinician and scheduling an INR check within 7 days.
6. Screen for malabsorption if PIVKA-II remains elevated after 8 weeks of dietary correction and supplementation.
7. Recheck PIVKA-II alongside undercarboxylated osteocalcin at 8 to 12 weeks post-intervention.